Gastrectomy News and Research

RSS

Study confirms benefits of robotic gastric cancer surgery

Surgery remains the primary curative treatment for gastric cancer, with laparoscopic gastrectomy (LG) established as a standard minimally invasive approach.

24 Aug 2026

Bariatric surgery linked to higher risk of developing alcohol problems

Your body absorbs alcohol much more rapidly after bariatric surgery. Patients need to know this when they choose the kind of surgery they will have.

25 Jun 2026

Weight-loss surgery for obese teens found to be cost-effective over 10 years

Metabolic and bariatric surgery for teens with severe obesity was found to be cost-effective over 10 years, according to the new analysis from Ann & Robert H. Lurie Children's Hospital of Chicago published in JAMA Network Open.

15 Jun 2026

New stent design could improve treatment of gastric leaks

Each year, about 250,000 Americans undergo sleeve gastrectomy, one of the most common weight-loss operations in the United States. For most patients, recovery is uneventful.

3 Jun 2026

Whole-body PET scans track metabolic recovery after weight-loss surgery

A novel PET imaging framework reveals that bariatric surgery impacts not only body weight, but also the metabolic function of multiple organs.

1 Jun 2026

Semaglutide helps patients who gain weight after bariatric surgery

New UCL research supports use of the weight loss drug semaglutide for patients who do not get enough benefit from bariatric surgery.

22 May 2026

The role of gut bacteria in sustained diabetes improvement

Changes in gut microbiota after bariatric surgery are strongly linked to altered metabolic health and sustained improvement in type 2 diabetes, according to a study led by researchers at the University of Gothenburg.

7 May 2026

Bariatric surgery offers greater long-term health protection for seniors than GLP-1 drugs

Metabolic and bariatric surgery offers significantly greater long-term protection against heart attack, stroke and death than widely-used GLP-1 drugs in older adults with obesity and diabetes, according to new real-world analysis study presented today at the annual meeting of the American Society for Metabolic and Bariatric Surgery.

6 May 2026

Bariatric surgery outperforms GLP-1 medications for obesity disease remission

Metabolic and bariatric surgery delivers significantly greater weight loss and higher rates of obesity-related disease remission than glucagon-like peptide-1 receptor agonists (GLP-1s), according to one of the largest and most comprehensive real-world comparisons of the two treatments.

6 May 2026

U.S. bariatric surgery rates drop significantly amid GLP-1 surge

The number of metabolic and bariatric surgery procedures in the United States dropped below 200,000 in 2024 for the first time since 2020, a more than 20% decline from the prior year, according to new research presented today at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery.

5 May 2026

Bariatric surgery improves outcomes for patients with obesity and chronic kidney disease

Metabolic and bariatric surgery, also known as weight-loss surgery, dramatically improves outcomes for patients with obesity and chronic kidney disease (CKD), significantly reducing the risk of kidney failure, major cardiovascular events and death, according to new research presented here today at the annual meeting of the American Society for Metabolic and Bariatric Surgery.

5 May 2026

GLP-1 use surges as surgery rates drop for severe obesity

Drawing on electronic health records from nearly 20 million patients with severe obesity, researchers from University of California San Diego find that GLP-1 prescriptions have grown exponentially -- from less than 4,600 prescriptions in 2018 to more than 1.4 million in 2025 -- according to a new real-world analysis presented today at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery.

5 May 2026

Bariatric surgery costs significantly less than GLP-1 drugs over two years

A new real-world analysis of more than 90,000 patients with obesity and type 2 diabetes finds metabolic and bariatric surgery is costs significantly less than weekly injections of GLP-1 drugs over a two-year period, according to a new research presented today at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery.

5 May 2026

GLP-1 drugs combined with surgery yield superior weight loss results

People who begin obesity treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) and then undergo metabolic and bariatric surgery achieve substantially greater weight loss than with the medications alone, according to new research presented today at the annual meeting of the American Society for Metabolic and Bariatric Surgery.

5 May 2026

UK patients seeking surgery overseas are returning with complications the NHS must treat

Outward medical tourism for surgery results in serious complications, creating challenges for the NHS and highlighting the need for better patient awareness.

16 Jan 2026

Bariatric surgery reshapes body fat and muscle more than GLP-1 drugs

Bariatric surgery and GLP-1 treatments reshape body composition differently, emphasizing the importance of sex and treatment choice in muscle preservation.

14 Jan 2026

Postoperative complications of medical tourism place growing financial burden on the NHS

The postoperative complications of medical tourism may be costing the NHS up to £20,000 per patient, suggest the findings of a rapid review of the available data, published in the open access journal BMJ Open.

13 Jan 2026

Cleveland Clinic study shows lasting benefits of weight-loss surgery over GLP-1 medicines

A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo weight-loss surgery live longer and face fewer serious health problems compared with those treated with GLP-1 receptor agonist medicines alone.

16 Sep 2025

Increasing numbers of bariatric surgery patients turn to GLP-1 drugs

Bariatric surgery is usually effective on its own for weight loss, but an increasing proportion of patients who undergo bariatric surgery start taking one of the new glucagon-like 1 peptide receptor agonist (GLP-1) weight-loss drugs in the years after their surgery, according to a new study led by researchers at the Johns Hopkins Bloomberg School of Public Health.

27 Aug 2025

NYU Langone Hospital—Suffolk performs first robotic cancer surgeries

Continuing its transformation since joining NYU Langone Health, the operative team at NYU Langone Hospital—Suffolk recently performed four complex robotic surgeries that had never been offered at the facility before, three of which successfully removed cancerous tumors from patients.

13 Aug 2025